1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDevelopment of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats (RFA-AI-27-014) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), NIH. This opportunity supports the development of medical countermeasures and enabling technologies to address chemical and radiation/nuclear (CRN) threats in civilian settings.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH Chemical & Radiation Countermeasures Funding (RFA-AI-27-014) – Apply by October 9, 2026 — BW&CO Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats Below is a brief summary. Please check the full solicitation before applying (link in resources section).
This NIH opportunity (RFA-AI-27-014) supports the development of medical countermeasures (MCMs) and enabling technologies to address chemical and radiation/nuclear (CRN) threats in civilian settings. The program is administered by NIAID through the Radiation and Nuclear Countermeasures Program (RNCP) and Chemical Countermeasures Research Program (CCRP).
It is designed to fund early and preclinical work that can diagnose, mitigate, or treat injuries following exposure. This is a forecasted opportunity with an Estimated Application Due Date: October 9, 2026 . Founders working in radiological, nuclear, or chemical threat preparedness should begin positioning now, as this is a complex NIH cooperative agreement with long lead times.
How much funding would I receive? Funding amounts are not specified in the solicitation , but we anticipate funding to range from $500k - $2m. What could I use the funding for?
Funding supports research and development of medical countermeasures and enabling technologies addressing CRN threats, including: Radiation and Nuclear Countermeasures Program (RNCP): Biomarkers of radiation damage Devices to assess and predict injury Products to improve survival and reduce morbidity across organ systems Chemical Countermeasures Research Program (CCRP): Preclinical development of products Technologies to mitigate or treat injury after exposure to Chemicals of Concern Solutions designed for post-exposure, civilian mass casualty settings All work must align with developing capabilities to diagnose, mitigate, or treat acute and delayed effects of radiation or chemical exposure during or after public health emergencies.
Are there any additional benefits I would receive? Not specified in the solicitation. What is the timeline to apply and when would I receive funding?
Estimated Post Date: July 10, 2026 Estimated Application Due Date: October 9, 2026 Estimated Award Date: July 1, 2027 Estimated Project Start Date: July 1, 2027 Additional timeline details are not specified in the solicitation . Where does this funding come from? This funding is provided by the National Institute of Allergy and Infectious Diseases (NIAID) on behalf of the NIH.
Sections 301 and 405 of the Public Health Service Act (42 USC 241 and 284) Federal Regulations: 42 CFR Part 52 and 2 CFR Part 200 The program is supported by a congressional mandate (Public Law 109-149, Dec. 30, 2005) to advance research addressing chemical and radiological threats. Who is eligible to apply?
For-profit organizations other than small businesses What companies and projects are likely to win?
Projects that align closely with the stated program goals, including: Development of medical countermeasures for radiation or chemical exposure Technologies addressing post-exposure treatment in civilian mass casualty scenarios Preclinical-stage innovations with clear pathways to mitigating injury or improving survival Tools for diagnostics, biomarkers, or injury assessment Further selection criteria are not specified in the solicitation .
Are there any restrictions I should know about? Funding instrument is a cooperative agreement No cost sharing or matching requirement Additional restrictions are not specified in the solicitation . How long will it take me to prepare an application?
Given this is an NIH cooperative agreement focused on preclinical and translational research, preparation timelines are typically substantial, but exact expectations are not specified in the solicitation .
Translating your technology into NIH-aligned positioning Mapping your solution to RNCP or CCRP priorities Structuring a competitive preclinical development narrative Managing the full application process ahead of the October 9, 2026 deadline Review solicitation here.
NIH Biotech Medical Countermeasures Medical Devices Healthtech xTech|Phantum Competition (ARM26BX01-NP003) AFRL - Multi-Spectrum Defensive Electronic Warfare (MSDEW) Advanced Research Announcement (ARA)
According to the current listing, eligibility includes: For-profit organizations (small businesses, other than small businesses). Confirm the full requirements in the official notice before applying.
The current listing shows $500,000 - $2,000,000 (anticipated). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats (RFA-AI-27-014) are due October 9, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats (RFA-AI-27-014) is funded by National Institute of Allergy and Infectious Diseases (NIAID), NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
National Institute of Allergy and Infectious Diseases (NIAID) Resource-Related Research Projects (R24 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), NIH. This program supports resource development projects to advance infectious disease and immunology research, aligning with NIAID's vision to improve human health through an integrated approach to infectious and immune-mediated disease research.
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), NIH. This funding opportunity supports investigator-initiated clinical trials requiring enhanced oversight, with durations up to 7 years, relevant to the NIAID mission of improving human health through infectious and immune-mediated disease research.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article